Orexigen(R) Therapeutics Initiates First Clinical Trial Of OREX-003 For The Mitigation Of Antipsychotic Associated Weight Gain
Oct 3rd 2008Drug InformationClinical Trials
Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, announced the initiation of its first clinical trial with OREX-003, a proprietary sustained release formulation of zonisamide plus olanzapine.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
